Therapeutic Human Polyclonals developed a transgenic mammalian platform that enhances the generation of monoclonal and polyclonal antibody therapeutics.
Roche paid $56.5 million for antibody technology company Therapeutic Human Polyclonals (THP). The company reports that the acquisition strengthens its expertise in therapeutic antibody research.
Roche plans to fully integrate THP into the Roche Pharma Center of Excellence for Protein Research organization in Penzberg, Germany.
A California-based company with a subsidiary in Germany, THP is focused on research in human antibody technologies. The company has developed a transgenic mammalian platform to create human antibodies. Roche reports that this technology will enable it to generate monoclonal and polyclonal antibody therapeutics with enhanced efficacy.